Novartis AG (NOVN.SW)
Makes medicines that treat cancer, heart disease, arthritis, and other serious illnesses
130.40+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+38.4%
The outlook
Novartis is trading near its 52-week high with price above both its 50- and 200-day moving averages, suggesting sustained upward momentum. Analyst consensus leans toward Hold, with the average price target sitting roughly 3% below current levels. The stock's trailing P/E of 24.1 reflects a premium valuation in the current market.
What’s behind the score
Analyst consensusHold — 2.7 avg of 21 analysts
Price trendAbove its 50- & 200-day averages
52-week range98% of the way from its 52-week low to high
Price targetAvg target -3% vs current price
Analyst price target
~12-month · 21 analysts125.98average target-3.4% vs now
Now 130.40
Low 95.93High 143.04
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$247.85B
52-wk high
131.28
52-wk low
91.56
50-day avg
121.89
200-day avg
116.04
Trailing P/E
24.1